Abstract
The effects of the addition of Vigabatrin, a new anti-epileptic drug, to the therapy of 128 patients with severe medically refractory epilepsy is reported. Forty two (33%) of patients experienced side effects, which were predominantly neurotropic. In 28 (22%), the drug was withdrawn because of these side effects. The commonest side effects were drowsiness and behavioural change. The remaining 100 patients were followed for a mean of 30 weeks (range 12-75). Forty one of these patients showed a marked improvement in seizure frequency (a 50% or more reduction when compared with the pre-trial period), and nine (7%) were rendered seizure free. Apparent tolerance to the effects of the drug were noted in five patients. An exacerbation of seizures may occur if the drug is withdrawn too quickly. Vigabatrin appears to be a promising new anti-epileptic drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Butler W. H., Ford G. P., Newberne J. W. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol. 1987;15(2):143–148. doi: 10.1177/019262338701500203. [DOI] [PubMed] [Google Scholar]
- Gram L., Klosterskov P., Dam M. gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol. 1985 Mar;17(3):262–266. doi: 10.1002/ana.410170307. [DOI] [PubMed] [Google Scholar]
- Gram L., Larsson O. M., Johnsen A., Schousboe A. Experimental studies of the influence of vigabatrin on the GABA system. Br J Clin Pharmacol. 1989;27 (Suppl 1):13S–17S. doi: 10.1111/j.1365-2125.1989.tb03455.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jung M. J., Lippert B., Metcalf B. W., Böhlen P., Schechter P. J. gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977 Nov;29(5):797–802. doi: 10.1111/j.1471-4159.1977.tb10721.x. [DOI] [PubMed] [Google Scholar]
- Loiseau P., Hardenberg J. P., Pestre M., Guyot M., Schechter P. J., Tell G. P. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia. 1986 Mar-Apr;27(2):115–120. doi: 10.1111/j.1528-1157.1986.tb03512.x. [DOI] [PubMed] [Google Scholar]
- Pedersen B., Højgaard K., Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res. 1987 Jan;1(1):74–76. doi: 10.1016/0920-1211(87)90054-4. [DOI] [PubMed] [Google Scholar]
- Rimmer E. M., Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet. 1984 Jan 28;1(8370):189–190. doi: 10.1016/s0140-6736(84)92112-3. [DOI] [PubMed] [Google Scholar]
- Schechter P. J., Hanke N. F., Grove J., Huebert N., Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology. 1984 Feb;34(2):182–186. doi: 10.1212/wnl.34.2.182. [DOI] [PubMed] [Google Scholar]
- Tartara A., Manni R., Galimberti C. A., Hardenberg J., Orwin J., Perucca E. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study. Epilepsia. 1986 Nov-Dec;27(6):717–723. doi: 10.1111/j.1528-1157.1986.tb03600.x. [DOI] [PubMed] [Google Scholar]
- Tassinari C. A., Michelucci R., Ambrosetto G., Salvi F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol. 1987 Sep;44(9):907–910. doi: 10.1001/archneur.1987.00520210009010. [DOI] [PubMed] [Google Scholar]